Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

Nature

Volumn 487, Issue 7408, 2012, Pages 482-485

  Archin, N M ^a   Liberty, A L ^a   Kashuba, A D ^a   Choudhary, S K ^a   Kuruc, J D ^a   Crooks, A M ^a   Parker, D C ^a   Anderson, E M ^b   Kearney, M F ^b   Strain, M C ^c   Richman, D D ^c   Hudgens, M G ^a   Bosch, R J ^d   Coffin, J M ^b   Eron, J J ^a   Hazuda, D J ^e   Margolis, D M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HISTONE DEACETYLASE INHIBITOR; VIRUS RNA; VORINOSTAT;

BIOMARKER; ENZYME ACTIVITY; GENOME; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIVITY; INHIBITOR; MOLECULAR ANALYSIS;

ACETYLATION; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DRUG EXPOSURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; UPREGULATION; VIREMIA; VIRUS LATENCY;

ACETYLATION; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION REGULATION, VIRAL; HISTONE DEACETYLASE INHIBITORS; HISTONES; HIV INFECTIONS; HIV-1; HUMANS; HYDROXAMIC ACIDS; PROVIRUSES; RISK ASSESSMENT; RNA, VIRAL; UP-REGULATION; VIREMIA; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84864203255     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11286     Document Type: Article

References (25)

1. Blankson, J. N., Persaud, D.&Siliciano, R. F. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53, 557-593 (2002).
2. Margolis, D. M. Histone deacetylase inhibitors and HIV latency. Curr. Opin. HIV AIDS 6, 25-29 (2011).
3. Van. Lint, C. et al. Transcriptional activation andchromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15, 1112-1120 (1996).
4. Archin, N. M. et al. Expression of latent human immunodeficiency type-1 is induced by novel and selective histone deacetylase inhibitors. AIDS 23, 1799-1806 (2009).
5. Archin, N. M. et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25, 207-212 (2009).
6. Contreras, X. et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284, 6782-6789 (2009).
7. Lehrman, G. et al. Depletion of latent HIV infection in vivo: a proof of concept study. Lancet 366, 549-555 (2005).
8. Archin, N. M. et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD41 T cells. AIDS 22, 1131-1135 (2008).
9. Siliciano, J. D. et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J. Infect. Dis. 195, 833-836 (2007).
10. Sagot-Lerolle, N. et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 22, 1125-1129 (2008).
11. Archin, N. M. et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or restingCD41cell infection. PLoSONE 5, e9390 (2010).
12. Keedy, K. S. et al. A limited group of class I histone deacetylases act to repress human immunodeficiency virus type-1 expression. J. Virol. 83, 4749-4756(2009).
13. Edelstein, L. C., Micheva-Viteva, S., Phelan, B. D. & Dougherty, J. P. Activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res. Hum. Retroviruses 25, 883-887 (2009).
14. Gui, C. Y. et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl Acad. Sci. USA 101, 1241-1246 (2004).
15. Du, L., Musson, D. G. & Wang, A. Q. High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum. Rapid Commun. Mass Spectrom. 19, 1779-1787 (2005).
16. Rubin, E. H. et al. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin. Cancer Res. 12, 7039-7045 (2006).
17. Hermankova, M. et al. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD41 T lymphocytes in vivo. J. Virol. 77, 7383-7392 (2003).
18. Palmer, S. et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41, 4531-4536 (2003).
19. Lee, J. H., Choy, M. L., Ngo, L., Foster, S. S. & Marks, P. A. Histone deacetylase inhibitor inducesDNAdamage, whichnormalbut not transformed cellscanrepair. Proc. Natl Acad. Sci. USA 107, 14639-14644 (2010).
20. Lee, J. H., Choy, M. L., Ngo, L., Venta-Perez, G. & Marks, P. A. Role of checkpoint kinase 1 (Chk1) in themechanismsof resistance to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 108, 19629-19634 (2011).
21. Israel-Ballard, K, et al. TaqManRT-PCRand VERSANTHIV-1RNA 3.0 (bDNA) assay quantification of HIV-1 RNA viral load in breast milk. J. Clin. Virol. 34, 253-256 (2005).
22. Robinson, L. H., Gale, C. V. & Kleim, J. P. Inclusion of full-length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibilityphenotyping. J. Virol. Methods104,147-160 (2002).
23. Radonić, A. et al. Guideline to reference gene selection for quantitative real-time PCR. Biochem. Biophys. Res. Commun. 313, 856-862 (2004).
24. May, R. C. et al. Change-Point Models to Estimate the Limit of Detection (Working Paper 26, University of North Carolina at Chapel Hill Biostatistics Technical Report Series, March 2012); available at http://biostats.bepress.com/ uncbiostat/papers/art26.
25. Tonelli, R. et al. G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLLAF9 independent. Leukemia 20, 1307-1310 (2006).